Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study

Outcome of patients with transplant glomerulopathy ( TG ) is poor. Using B‐cell targeting molecules represent a rational strategy to treat TG during chronic antibody‐mediated rejection. In this pilot study, 21 patients with this diagnosis received four doses of intravenous immunoglobulins and two doses of rituximab ( IVIG / RTX group). They were retrospectively compared with a untreated control group of 10 patients. At 24 months post‐biopsy,...